Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 12/20 | 0.58 |
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918127 | 1.00 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL15354859 | 1.00 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918130 | 0.92 | PGR (0.79) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL2168200 | 0.92 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL12473404 | 0.92 | PGR (0.69) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL2168665 | 0.91 | PGR (0.68) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL16479391 | 0.91 | PGR (0.68) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13918110 | 0.88 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL16016504 | 0.88 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL544872 | 0.88 | PGR (0.67) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107925-B1 | PROCESS FOR THE PRODUCTION OF 21-METHOXY-11-BETA-PHENYL-19-NOR-PREGNA-4,9-DIENE-3,20-DIONE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2018-05-16 | — | — | EP | disclosed |
| US-9683010-B2 | Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives | RICHTER GEDEON NYRT. (HU) | 2017-06-20 | — | — | US | disclosed |
| US-9683010-B2 | Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives | RICHTER GEDEON NYRT. (HU) | 2017-06-20 | — | — | US | disclosed |
| US-20160326211-A1 | PROCESS FOR THE PRODUCTION OF 21-METHOXY-11-BETA-PHENYL-19-NOR-PREGNA-4,9-DIENE-3,20-DIONE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-11-10 | — | — | US | disclosed |
| US-20160326211-A1 | PROCESS FOR THE PRODUCTION OF 21-METHOXY-11-BETA-PHENYL-19-NOR-PREGNA-4,9-DIENE-3,20-DIONE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2016-11-10 | — | — | US | disclosed |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569276-B2 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-29 | — | — | US | disclosed |
| US-8003629-B2 | 21-substituted progesterone derivatives as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2348031-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348030-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20060276443-A1 | 21-substituted progesterone derivatives as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2006-12-07 | — | — | US | disclosed |
| US-7087591-B2 | 21-substituted progesterone derivatives as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2005-06-30 | — | — | US | disclosed |
| US-20050143364-A1 | 21-Substituted progesterone derivatives as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2005-06-30 | — | — | US | disclosed |
| US-6900193-B1 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-31 | — | — | US | disclosed |
| US-6861415-B2 | 21-substituted progesterone derivatives as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1265911-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020025951-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | NATIONAL INSTITUTES OF HEALTH | 2002-02-28 | — | — | US | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0900234-B1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | CYP19A1, HSD17B11, CYP17A1 | PGR 4/4885NR3C1 61/4885AR 225/4885 |
| US-20050143364-A1 | 21-Substituted progesterone derivatives as new antiprogestational agents | HSD17B11, NR5A1, HSD17B3 | PGR 9/4885NR3C1 54/4885AR 107/4885 |
| US-20160326211-A1 | PROCESS FOR THE PRODUCTION OF 21-METHOXY-11-BETA-PHENYL-19-NOR-PREGNA-4,9-DIENE-3,20-DIONE DERIVATIVES | CYP17A1, CYP21A2, HSD17B7 | PGR 30/4885NR3C1 37/4885AR 56/4885 |
| US-20060276443-A1 | 21-substituted progesterone derivatives as new antiprogestational agents | HSD17B11, HSD17B3, HSD3B1 | PGR 10/4885NR3C1 67/4885AR 112/4885 |
| US-20020025951-A1 | 21-SUBSTITUTED PROGESTERONE DERIVATIVES AS NEW ANTIPROGESTATIONAL AGENTS | HSD17B11, HSD3B1, HSD3B2 | PGR 11/4885NR3C1 58/4885AR 100/4885 |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | HSD17B11, NR5A1, CYP19A1 | PGR 5/4885NR3C1 27/4885AR 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.